950160 — Kolon TissueGene Share Price
0.000.00%
Last trade - 00:00- KR₩22tn
- KR₩22tn
- $3.72m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 152.76 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4,076.21 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -15.68% | ||
| Return on Equity | -26.3% | ||
| Operating Margin | -433.58% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 3.01 | 3.5 | 7.32 | 2.84 | 3.72 | n/a | n/a | 7.27% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Kolon TissueGene, Inc. is a biopharmaceutical company engaged in developing clinical-stage advanced cell therapies. The Company is developing advanced cell therapies to target various orthopedic diseases and degenerative disorders. Its platform technology consists of a combination of allogeneic primary cells combined with genetically modified cells in one injectable therapeutic dose. TG-C, its lead product candidate, is developed for treating osteoarthritis (OA) of the knee. TG-C is an allogeneic (donor) cell and gene therapy involving primary human chondrocytes (cartilage cells) and human cells transduced to express the therapeutic growth factor TGF-ß1, which is delivered via an intra-articular injection into the knee. Its product pipelines fall under the categories osteoarthritis, musculoskeletal system disorder, and vet medicine. It is also developing therapies for musculoskeletal system disorders, such as rheumatoid arthritis, meniscus, and spinal discs.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 9th, 1999
- Public Since
- November 6th, 2017
- No. of Shareholders
- 39,057
- No. of Employees
- 56
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Korea Exchange - KOSDAQ
- Shares in Issue
- 95,473,854
- Address
- 9713 Key West Avenue, Suite 300, ROCKVILLE, 20850
- Web
- https://www.tissuegene.com/
- Phone
- +1 3019216000
- Auditors
- Seohyun Accounting Group
Upcoming Events for 950160
Q2 2025 Kolon TissueGene Inc Earnings Release
Similar to 950160
3Billion
Korea Exchange - KOSDAQ
ABion
Korea Exchange - KOSDAQ
ABL Bio
Korea Exchange - KOSDAQ
Amicogen
Korea Exchange - KOSDAQ
AprilBio Co
Korea Exchange - KOSDAQ
FAQ
What is the Kolon TissueGene share price?
As of Today at 03:37 UTC, shares in Kolon TissueGene are trading at KR₩45,400. This share price information is delayed by 15 minutes.
How has the Kolon TissueGene share price performed this year?
Shares in Kolon TissueGene last closed at KR₩45,400 and the price had moved by +293.85% over the past 365 days. In terms of relative price strength the Kolon TissueGene share price has outperformed the FTSE Developed Asia Pacific Index by +298.35% over the past year.
What are the analyst and broker recommendations for Kolon TissueGene?
The overall consensus recommendation for Kolon TissueGene is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Kolon TissueGene dividend yield?
Kolon TissueGene does not currently pay a dividend.
Does Kolon TissueGene pay a dividend?
Kolon TissueGene does not currently pay a dividend.
When does Kolon TissueGene next pay dividends?
Kolon TissueGene does not currently pay a dividend.
How do I buy Kolon TissueGene shares?
To buy shares in Kolon TissueGene you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Kolon TissueGene?
As of the previous close price of KR₩45,400, shares in Kolon TissueGene had a market capitalisation of KR₩22tn.
Where are Kolon TissueGene shares listed?
Here are the trading details for Kolon TissueGene:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 950160
What kind of share is Kolon TissueGene?
Based on an overall assessment of its quality, value and momentum Kolon TissueGene is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Kolon TissueGene share price forecast for 2025?
The analyst consensus target price for shares in Kolon TissueGene is KR₩72,000. That is 58.59% above the last closing price of KR₩45,400.
Analysts covering Kolon TissueGene currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the Kolon TissueGene share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Kolon TissueGene. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +200.06%.
As of the last closing price of KR₩45,400, shares in Kolon TissueGene were trading +78.12% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Kolon TissueGene PE Ratio?
The Kolon TissueGene PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩45,400.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Kolon TissueGene?
Kolon TissueGene's management team is headed by:
- Seong Su Han - CCE
- Moon Jong Noh - CCE
- Harrison Noh - VFN
- Sean Woo - GCN
- Kwan Lee - OTH